Evaluation of Efficacy and Safety of Naftin 1% Cream in Adolescent Subjects With Tinea Cruris

NCT01885156 | Completed Phase 3

• 1 other identifier: MUS 90200_3028_1
• Study Type: interventional
• Target: 65
• Locations: 3 countries
• Sites: 5

Brief Summary

To see how well Naftin 1% cream works when applied once daily to the affected area. The results will be compared to those using a placebo cream, which is a cream with no active ingredient. Safety will also be measured.

Conditions

Tinea Cruris; Jock Itch

Outcome Measures

Primary Outcomes (1)

• Safety of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).

  \- Summarization of AEs (local and systemic)

  Week 6

Secondary Outcomes (1)

• Efficacy of Naftin® 1% Cream, applied once daily for 4 weeks, compared to vehicle for treatment of subjects with KOH and culture positive symptomatic tinea cruris in adolescent subjects (aged 12 years to 17 years, 11 months).

  Week 6

Study Arms (2)

Placebo Cream

PLACEBO COMPARATOR

Topically applied once daily

Drug: Placebo Cream

Naftin 1% Cream

EXPERIMENTAL

Topically applied once daily

Drug: Naftin 1% Cream

Interventions

Naftin 1% Cream DRUG

Topically applied once a day

Naftin 1% Cream

Placebo Cream DRUG

Topically applied once a day

Placebo Cream

Eligibility Criteria

• Age: 12 Years - 17 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17)

You may qualify if:

• Review and sign statement of Informed Consent and HIPAA authorization.
• Males or non-pregnant females ≥ 12 years of age to 17 years, 11 months, of any race or sex. Females of child-bearing potential must have a negative urine pregnancy test.
• The parent/legal guardian must complete the informed consent process AND the subject must complete the assent process and sign the appropriate form (if age appropriate).
• Presence of tinea cruris characterized by clinical evidence of a tinea infection (at least moderate erythema, moderate scaling, and mild pruritus) based on signs and symptoms.
• KOH positive baseline skin scrapings obtained from the site most severely affected or a representative site of the overall severity.
• Subjects must be in good health and free from any clinically significant disease that might interfere with the study evaluations.
• Subject must be able to understand the requirements of the study and willing to comply with the study requirements.

You may not qualify if:

• A life threatening condition (ex. autoimmune deficiency syndrome, cancer, unstable angina, or myocardial infarction) within the last 6 months.
• Subjects with abnormal findings - physical or laboratory - that are considered by the investigator to be clinically important and indicative of conditions that might complicate interpretation of study results.- Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
• Subjects with a known hypersensitivity to study medications or their components.
• Subjects who have a recent history or who are currently known to abuse alcohol or drugs.
• Uncontrolled diabetes mellitus.
• Hemodialysis or chronic ambulatory peritoneal dialysis therapy.
• Current diagnosis of immunocompromising conditions.
• Atopic or contact dermatitis.
• Severe dermatophytoses, mucocutaneous candidiasis, or bacterial skin infection.
• Female subject who is pregnant or lactating, who is not using or does not agree to use an acceptable form of contraception during the study, or who intends to become pregnant during the study (females who are surgically sterilized for at least 2 years are not considered to be of childbearing potential).
• Subjects using the following medications:
• Topical anti-fungal therapy, powders or topical corticosteroids applied within 14 days prior to randomization. Terbinafine, butenafine, and naftifine (topical) within 30 days prior to randomization.
• Oral anti-fungal therapies within 3 months of randomization (8 months for oral terbinafine).
• Systemic antibiotic or corticosteroid treatment within 30 days of randomization.
• Any other significant treatments, except hormonal contraception and multivitamin, at the discretion of the investigator that would interfere with study treatment.

Sponsors & Collaborators

• Merz North America, Inc.: lead

Study Sites (5)

Merz Investigational Site # 501001

Belize City, Belize

Location

Merz Investigational Site # 501002

Belize City, Belize

Location

Merz Investigative Site # 180002

San Cristóbal, Dominican Republic

Location

Merz Investigative Site # 180001

Santo Domingo, Dominican Republic

Location

Merz Investigative Site # 504001

San Pedro Sula, Honduras

Location

MeSH Terms

Conditions

Tinea Cruris

Interventions

naftifine

Condition Hierarchy (Ancestors)

Tinea; Dermatomycoses; Mycoses; Bacterial Infections and Mycoses; Infections; Skin Diseases, Infectious; Intertrigo; Dermatitis; Skin Diseases; Skin and Connective Tissue Diseases; Skin Diseases, Eczematous

Study Officials

• Stefan Plaum, MD

  Merz North America, Inc.

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 3
• Allocation: RANDOMIZED
• Masking: QUADRUPLE
• Who Masked: PARTICIPANT, CARE PROVIDER, INVESTIGATOR, OUTCOMES ASSESSOR
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: June 20, 2013
• First Posted: June 24, 2013
• Study Start: August 1, 2013
• Primary Completion: November 1, 2013
• Study Completion: November 1, 2013
• Last Updated: April 15, 2015

Record last verified: 2015-03

Locations

HO (1); BE (2); DO (2)